Drugs / MVA-NP+M1
last change Oct 2018 re-read 2 minutes ago

MVA-NP+M1

Vaccine

Developed for
influenza
Investigated by
Barinthus Biotherapeutics · University of Oxford

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03300362 Oct 2017 → Oct 2018 influenza Barinthus Biotherapeutics Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MVA-NP+M1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300362
Modality Vaccine “a new vaccine MVA-NP+M1” NCT03300362